Proxy Votes Now

Home › Funds › John Hancock › Health Sciences Trust

Health Sciences Trust (JAFKX) proxy voting record 2025-2026

Fund family: John Hancock · Filed by JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 756913) · SEC series S000008239

Share classes and tickers: JAFKX (C000022444), JAFMX (C000022442), JEHSX (C000022443)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,299 with, 27 against, 16 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with John Hancock as a whole

The same two figures as John Hancock’s manager page (290,519 ballot items across 99 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsJohn HancockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.0%1,24290.1%242,172
Backed environmental and social shareholder proposals at US companiesn/a813.4%1,935

Where this fund voted differently from most John Hancock funds

Each ballot item this fund voted is set against the votes of the other John Hancock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most John Hancock funds on 145 items (13.7% of the 1,062 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost John Hancock fundsMgmtResult
CYTOKINETICS, INCORPORATED2026-05-272 wordings Election of Class I Directors for terms expiring in 2029. Edward M. Kaye, M.D.WithholdFOR — 10 of 10 John Hancock fundsAgainst—
BIO-RAD LABORATORIES, INC.2026-04-21Nominees: Arnold A. PinkstonAgainstFOR — 8 of 8 John Hancock fundsAgainstPassed (calculated), 88.8% support
BIO-RAD LABORATORIES, INC.2026-04-21Nominees: Melinda LitherlandAgainstFOR — 8 of 8 John Hancock fundsAgainstPassed (calculated), 88.3% support
RHYTHM PHARMACEUTICALS, INC.2026-06-24Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.ForAGAINST — 7 of 7 John Hancock fundsForApproved, 81.5% support
MODERNA, INC.2026-05-06To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified or such director's earlier death, resignation or removal. Sandra HForAGAINST — 6 of 6 John Hancock fundsFor—
GUARDANT HEALTH, INC.2026-06-17Election of Class II Directors Ian ClarkForWITHHOLD — 6 of 6 John Hancock fundsFor—
GUARDANT HEALTH, INC.2026-06-17Election of Class II Directors Manuel Hidalgo MedinaForWITHHOLD — 6 of 6 John Hancock fundsFor—
IONIS PHARMACEUTICALS, INC.2026-06-04Election of Directors Joan E. HermanAgainstFOR — 6 of 6 John Hancock fundsAgainst—
IONIS PHARMACEUTICALS, INC.2026-06-04Election of Directors Spencer R. BerthelsenAgainstFOR — 6 of 6 John Hancock fundsAgainst—
ABBVIE INC.2026-05-08Shareholder Stockholder Proposal - to Adopt a Policy to Require an Independent ChairAgainstFOR — 9 of 10 John Hancock fundsForNot approved, 39.6% support
ABBVIE INC.2026-05-08Election of Class II Directors Frederick H. WaddellAgainstFOR — 9 of 10 John Hancock fundsAgainst—
ABBVIE INC.2026-05-08Election of Class II Directors Jennifer L. DavisAgainstFOR — 9 of 10 John Hancock fundsAgainst—
ABBVIE INC.2026-05-08Election of Class II Directors Melody B. MeyerAgainstFOR — 9 of 10 John Hancock fundsAgainst—
REGENERON PHARMACEUTICALS, INC.2026-06-12Election of Directors Christine A. PoonForAGAINST — 5 of 5 John Hancock fundsFor—
REGENERON PHARMACEUTICALS, INC.2026-06-12Election of Directors Craig B. Thompson, M.D.ForAGAINST — 5 of 5 John Hancock fundsFor—
REGENERON PHARMACEUTICALS, INC.2026-06-12Election of Directors Joseph L. Goldstein, M.D.ForAGAINST — 5 of 5 John Hancock fundsFor—
NATERA, INC.2026-06-11DIRECTOR: Herm Rosenman*AbstainFOR — 5 of 5 John Hancock fundsAgainst—
NATERA, INC.2026-06-11DIRECTOR: Jonathan Sheena*AbstainFOR — 5 of 5 John Hancock fundsAgainst—
NATERA, INC.2026-06-11DIRECTOR: Rowan Chapman*AbstainFOR — 5 of 5 John Hancock fundsAgainst—
INSMED INCORPORATED2026-05-13DIRECTOR: C. Desjardins, Ph.D.AbstainFOR — 5 of 5 John Hancock fundsAgainst—
REPLIGEN CORPORATION2026-05-14Election of Directors Carrie Eglinton MannerForAGAINST — 5 of 5 John Hancock fundsFor—
REPLIGEN CORPORATION2026-05-14Election of Directors Glenn P. MuirForAGAINST — 5 of 5 John Hancock fundsFor—
MADRIGAL PHARMACEUTICALS INC.2026-06-172 wordings Re-election of Class I directors: Julian BakerWithholdFOR — 5 of 5 John Hancock fundsAgainstElected, 88.6% support
KRYSTAL BIOTECH, INC.2026-05-15DIRECTOR: Christopher MasonForABSTAIN — 5 of 5 John Hancock fundsFor—
KRYSTAL BIOTECH, INC.2026-05-15DIRECTOR: Krish S. KrishnanForABSTAIN — 5 of 5 John Hancock fundsFor—
Show all 145
Items 26 to 145.
CompanyMeetingItemThis fundMost John Hancock fundsMgmtResult
RHYTHM PHARMACEUTICALS, INC.2026-06-24DIRECTOR: David W.J. McGirrForABSTAIN — 5 of 5 John Hancock fundsFor—
DENALI THERAPEUTICS INC.2026-06-03DIRECTOR: David Schenkein, M.D.ForABSTAIN — 5 of 5 John Hancock fundsFor—
DENALI THERAPEUTICS INC.2026-06-03DIRECTOR: Jennifer CookForABSTAIN — 5 of 5 John Hancock fundsFor—
STOKE THERAPEUTICS, INC.2026-06-03To approve, on an advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 5 of 5 John Hancock fundsForPassed (calculated), 72.9% support
OCULAR THERAPEUTIX, INC.2026-06-10To approve an advisory vote on named executive officer compensation.ForAGAINST — 5 of 5 John Hancock fundsFor—
PROCEPT BIOROBOTICS CORPORATION2026-06-09Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.ForAGAINST — 5 of 5 John Hancock fundsForApproved, 73.1% support
MOLINA HEALTHCARE, INC.2026-05-06To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers.ForAGAINST — 10 of 12 John Hancock fundsForPassed (calculated), 52.8% support
BRIGHTSPRING HEALTH SERVICES, INC.2026-05-212 wordings Election of Class II directors Olivia KirtleyForWITHHOLD — 7 of 8 John Hancock fundsFor—
REVVITY, INC.2026-04-28Shareholder To approve the shareholder proposal regarding Executives to Retain Significant Stock.AgainstFOR — 9 of 11 John Hancock fundsForFailed (calculated), 23.1% support
ROIVANT SCIENCES LTD.2025-09-10DIRECTOR: Keith ManchesterForABSTAIN — 4 of 4 John Hancock fundsFor—
ROIVANT SCIENCES LTD.2025-09-10DIRECTOR: Matthew GlineForABSTAIN — 4 of 4 John Hancock fundsFor—
ROIVANT SCIENCES LTD.2025-09-10DIRECTOR: Melissa EpperlyForABSTAIN — 4 of 4 John Hancock fundsFor—
CELCUITY INC.2026-05-14DIRECTOR: Leo T. FurchtAbstainFOR — 4 of 4 John Hancock fundsAgainst—
MONTE ROSA THERAPEUTICS, INC.2026-06-11To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Anthony Manning, Ph.D.ForWITHHOLD — 4 of 4 John Hancock fundsFor—
BRIDGEBIO PHARMA, INC.2026-06-22DIRECTOR: Hannah A. Valantine, MDForABSTAIN — 6 of 7 John Hancock fundsFor—
BRIDGEBIO PHARMA, INC.2026-06-22To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.ForAGAINST — 6 of 7 John Hancock fundsForApproved, 82.9% support
ELI LILLY AND COMPANY2026-05-04Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair.AgainstFOR — 9 of 12 John Hancock fundsForNot approved, 33.7% support
MOLINA HEALTHCARE, INC.2026-05-06To consider and approve an amendment to the Company's 2025 Equity Incentive Plan to increase the number of shares available for issuance under such plan.ForAGAINST — 7 of 9 John Hancock fundsForPassed (calculated), 73.5% support
BOSTON SCIENTIFIC CORPORATION2026-04-30Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."AgainstFOR — 5 of 6 John Hancock fundsForNot approved, 42.8% support
ZOETIS INC.2026-05-20Shareholder Shareholder proposal to permit shareholder action by written consent.AgainstFOR — 5 of 6 John Hancock fundsFor—
SUMMIT THERAPEUTICS INC.2026-06-10DIRECTOR: Mahkam ZanganehForABSTAIN — 3 of 3 John Hancock fundsFor—
SUMMIT THERAPEUTICS INC.2026-06-10DIRECTOR: Manmeet S. SoniForABSTAIN — 3 of 3 John Hancock fundsFor—
SUMMIT THERAPEUTICS INC.2026-06-10DIRECTOR: Robert W. DugganForABSTAIN — 3 of 3 John Hancock fundsFor—
SUMMIT THERAPEUTICS INC.2026-06-10DIRECTOR: Yu (Michelle) XiaForABSTAIN — 3 of 3 John Hancock fundsFor—
PRAXIS PRECISION MEDICINES, INC.2026-06-10To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified. William YoungForWITHHOLD — 5 of 6 John Hancock fundsFor—
MIRUM PHARMACEUTICALS, INC.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Lon Cardon, Ph.D., FMedSciForWITHHOLD — 3 of 3 John Hancock fundsFor—
MIRUM PHARMACEUTICALS, INC.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Timothy WalbertForWITHHOLD — 3 of 3 John Hancock fundsFor—
MIRUM PHARMACEUTICALS, INC.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. William FaireyForWITHHOLD — 3 of 3 John Hancock fundsFor—
KODIAK SCIENCES INC.2026-06-02Elect three Class II directors nominated by our board and named in this proxy statement. Charles A. BancroftForWITHHOLD — 3 of 3 John Hancock fundsFor—
LIQUIDIA CORPORATION2026-06-16Election of Directors: Katie Rielly-GauvinForWITHHOLD — 3 of 3 John Hancock fundsForPassed (calculated), 92.2% support
LIQUIDIA CORPORATION2026-06-16Election of Directors: Ramandeep SinghForWITHHOLD — 3 of 3 John Hancock fundsForPassed (calculated), 91.6% support
RELAY THERAPEUTICS, INC.2026-06-09To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Claire Mazumdar, Ph.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
RELAY THERAPEUTICS, INC.2026-06-09To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Douglas S. IngramForWITHHOLD — 3 of 3 John Hancock fundsFor—
TANGO THERAPEUTICS, INC.2026-06-04Election of Class II Directors Kanishka PothulaForWITHHOLD — 3 of 3 John Hancock fundsFor—
TANGO THERAPEUTICS, INC.2026-06-04Election of Class II Directors Mace Rothenberg, M.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
TANGO THERAPEUTICS, INC.2026-06-04Election of Class II Directors Malte Peters, M.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
IOVANCE BIOTHERAPEUTICS, INC.2026-06-10To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.AgainstFOR — 3 of 3 John Hancock fundsAgainst—
TARSUS PHARMACEUTICALS, INC.2026-06-25To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. Andrew GoldbergForWITHHOLD — 3 of 3 John Hancock fundsFor—
ENLIVEN THERAPEUTICS, INC.2026-06-09To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Lori Kunkel, M.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
IDEAYA BIOSCIENCES, INC.2026-06-16To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; M. Garret Hampton, Ph.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
BEAM THERAPEUTICS INC.2026-06-03Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. Christi ShawForAGAINST — 3 of 3 John Hancock fundsFor—
BEAM THERAPEUTICS INC.2026-06-03Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John Maraganore, Ph.D.ForAGAINST — 3 of 3 John Hancock fundsFor—
XENCOR, INC.2026-06-16Approval of the amendment to the Company's Amended and Restated 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 4,000,000 shares; andForAGAINST — 3 of 3 John Hancock fundsForApproved, 82.0% support
PALVELLA THERAPEUTICS, INC2026-06-10Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares.ForAGAINST — 3 of 3 John Hancock fundsFor—
PALVELLA THERAPEUTICS, INC2026-06-10Election of three director nominees to serve as Class III directors whose term will expire in 2029. Todd C. DavisForWITHHOLD — 3 of 3 John Hancock fundsFor—
VERA THERAPEUTICS, INC.2026-05-21DIRECTOR: Michael M Morrissey PhDForABSTAIN — 3 of 3 John Hancock fundsFor—
BIOHAVEN LTD2026-04-28Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Irina Antonijevic, M.D., Ph.D.ForAGAINST — 3 of 3 John Hancock fundsForElected, 84.0% support
BIOHAVEN LTD2026-04-28Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Michael T. HeffernanForAGAINST — 3 of 3 John Hancock fundsForElected, 83.5% support
BIOHAVEN LTD2026-04-28Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Robert J. HuginForAGAINST — 3 of 3 John Hancock fundsForElected, 84.0% support
STOKE THERAPEUTICS, INC.2026-06-03DIRECTOR: Adrian Krainer, Ph.D.ForABSTAIN — 3 of 3 John Hancock fundsFor—
NURIX THERAPEUTICS, INC.2026-05-15DIRECTOR: Arthur T. Sands, M.D.ForABSTAIN — 3 of 3 John Hancock fundsFor—
NURIX THERAPEUTICS, INC.2026-05-15DIRECTOR: Paul M. SilvaForABSTAIN — 3 of 3 John Hancock fundsFor—
ULTRAGENYX PHARMACEUTICAL INC.2026-05-14Approval of the Third Amended and Restated 2023 Incentive Plan.ForAGAINST — 3 of 3 John Hancock fundsForApproved, 68.9% support
NUVATION BIO INC.2026-05-21DIRECTOR: Robert BazemoreForABSTAIN — 3 of 3 John Hancock fundsFor—
NUVATION BIO INC.2026-05-21DIRECTOR: Robert Mashal, M.D.ForABSTAIN — 3 of 3 John Hancock fundsFor—
TYRA BIOSCIENCES, INC.2026-05-28To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified. Robert MoreForWITHHOLD — 3 of 3 John Hancock fundsFor—
OCULAR THERAPEUTIX, INC.2026-06-10DIRECTOR: Merilee RainesForABSTAIN — 3 of 3 John Hancock fundsFor—
OCULAR THERAPEUTIX, INC.2026-06-10DIRECTOR: Pravin U. Dugel, M.D.ForABSTAIN — 3 of 3 John Hancock fundsFor—
RAPPORT THERAPEUTICS, INC.2026-06-10DIRECTOR: Robert J. PerezForABSTAIN — 3 of 3 John Hancock fundsForPassed (calculated), 88.8% support
PROCEPT BIOROBOTICS CORPORATION2026-06-092 wordings Election of Class II directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Antal DesaiForWITHHOLD — 3 of 3 John Hancock fundsFor—
ORIC PHARMACEUTICALS, INC.2026-06-18To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Mardi C. DierForWITHHOLD — 3 of 3 John Hancock fundsFor—
ALUMIS INC2026-06-30DIRECTOR: Zhengbin Yao, Ph.D.ForABSTAIN — 3 of 3 John Hancock fundsFor—
CULLINAN THERAPEUTICS, INC.2026-06-16DIRECTOR: Nadim AhmedForABSTAIN — 3 of 3 John Hancock fundsFor—
CULLINAN THERAPEUTICS, INC.2026-06-16DIRECTOR: Stephen WebsterForABSTAIN — 3 of 3 John Hancock fundsFor—
OLEMA PHARMACEUTICALS, INC.2026-06-17DIRECTOR: Yi LarsonForABSTAIN — 3 of 3 John Hancock fundsFor—
ALLOGENE THERAPEUTICS, INC.2026-06-18Election of Directors Deborah MessemerForWITHHOLD — 3 of 3 John Hancock fundsFor—
ALLOGENE THERAPEUTICS, INC.2026-06-18Election of Directors Owen Witte, M.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
ALLOGENE THERAPEUTICS, INC.2026-06-18Election of Directors Vicki Sato, Ph.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
ROCKET PHARMACEUTICALS, INC.2026-05-20The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal; Peter Fong, Ph.D.WithholdFOR — 3 of 3 John Hancock fundsAgainst—
AURA BIOSCIENCES, INC.2026-06-11DIRECTOR: David JohnsonForABSTAIN — 3 of 3 John Hancock fundsFor—
BEONE MEDICINES AG2026-06-11THAT MS. SHALINI SHARP BE AND IS HEREBY RE-ELECTED TO SERVE AS A DIRECTOR OF THE COMPANY FOR A TERM EXTENDING UNTIL COMPLETION OF THE 2027 ANNUAL GENERAL MEETINGAgainstFOR — 3 of 3 John Hancock fundsAgainst—
BETA BIONICS, INC.2026-05-21To elect two Class I directors, as nominated by the Board of Directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Christy JonesForWITHHOLD — 3 of 3 John Hancock fundsFor—
ENTRADA THERAPEUTICS, INC.2026-06-10Election of Directors Bernhardt Zeiher, M.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
ENTRADA THERAPEUTICS, INC.2026-06-10Election of Directors Peter S. Kim, Ph.D.ForWITHHOLD — 3 of 3 John Hancock fundsFor—
SIONNA THERAPEUTICS, INC.2026-06-17DIRECTOR: Marcella K. Ruddy, MDForABSTAIN — 3 of 3 John Hancock fundsFor—
SIONNA THERAPEUTICS, INC.2026-06-17DIRECTOR: Peter A. Thompson, M.D.ForABSTAIN — 3 of 3 John Hancock fundsFor—
STRYKER CORPORATION2026-05-06Election of Directors. Emmanuel P. MacedaForAGAINST — 6 of 8 John Hancock fundsFor—
WATERS CORPORATION2026-01-27Approve adjourning the Special Meeting, if necessary, (a) to solicit additional proxies if there are insufficient votes to approve the Share Issuance Proposal, (b) if insufficient shares of Waters Common Stock are represented (online or by proxy) to conduct business at the Special Meeting, and (c) tAgainstFOR — 6 of 8 John Hancock fundsAgainst—
CYTOKINETICS, INCORPORATED2026-05-27Election of Class I Directors for terms expiring in 2029. Wendell Wierenga, Ph.D.WithholdFOR — 7 of 10 John Hancock fundsAgainst—
VERTEX PHARMACEUTICALS INCORPORATED2026-05-13Shareholder Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.AgainstFOR — 4 of 5 John Hancock fundsForApproved, 57.0% support
HCA HEALTHCARE, INC.2026-04-23Shareholder Stockholder proposal, if properly presented at the meeting, regarding shareholders' right to act by written consent.AgainstFOR — 4 of 5 John Hancock fundsFor—
IDEXX LABORATORIES, INC.2026-05-12Shareholder Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six).AgainstFOR — 4 of 5 John Hancock fundsFor—
PROTAGONIST THERAPEUTICS, INC.2026-06-17DIRECTOR: Dinesh V. Patel, Ph.D.ForABSTAIN — 4 of 5 John Hancock fundsFor—
PROTAGONIST THERAPEUTICS, INC.2026-06-17To approve the adoption of the Company's 2026 Equity Incentive Plan.ForAGAINST — 4 of 5 John Hancock fundsForApproved, 84.4% support
CRINETICS PHARMACEUTICALS, INC.2026-06-18To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders; Caren DeardorfForWITHHOLD — 4 of 5 John Hancock fundsFor—
CRINETICS PHARMACEUTICALS, INC.2026-06-18To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders; Stephanie S. Okey, M.S.ForWITHHOLD — 4 of 5 John Hancock fundsFor—
NUVALENT, INC.2026-06-16Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.ForWITHHOLD — 4 of 5 John Hancock fundsForElected, 81.5% support
ALNYLAM PHARMACEUTICALS, INC.2026-05-20To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.AgainstFOR — 5 of 7 John Hancock fundsAgainstElected, 89.3% support
THE CIGNA GROUP2026-04-22Shareholder Shareholder Proposal - Shareholder Right to Act by Written ConsentAgainstFOR — 6 of 9 John Hancock fundsForFailed (calculated), 47.9% support
REVOLUTION MEDICINES, INC.2026-06-18DIRECTOR: Alexis BorisyForABSTAIN — 3 of 4 John Hancock fundsFor—
WEST PHARMACEUTICAL SERVICES, INC.2026-05-04Shareholder Shareholder proposal regarding an independent Board Chair policy.AgainstFOR — 4 of 6 John Hancock fundsForNot approved, 46.4% support
SPYRE THERAPEUTICS INC.2026-05-27DIRECTOR: Laurie StelzerForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: David HallalForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Katie PengForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Kristina BurowForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Michael GilmanForABSTAIN — 3 of 4 John Hancock fundsFor—
COGENT BIOSCIENCES, INC.2026-06-09DIRECTOR: Arlene M. MorrisForABSTAIN — 3 of 4 John Hancock fundsFor—
COGENT BIOSCIENCES, INC.2026-06-09DIRECTOR: Dr. Chris CainForABSTAIN — 3 of 4 John Hancock fundsFor—
COGENT BIOSCIENCES, INC.2026-06-09DIRECTOR: Todd ShegogForABSTAIN — 3 of 4 John Hancock fundsFor—
DIANTHUS THERAPEUTICS, INC.2026-05-21To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeForWITHHOLD — 3 of 4 John Hancock fundsFor—
DISC MEDICINE, INC.2026-06-18To elect each of the following Class III nominees to the Board of Directors as set forth below: Donald Nicholson, Ph.D.ForWITHHOLD — 3 of 4 John Hancock fundsFor—
MBX BIOSCIENCES2026-06-04Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersForWITHHOLD — 3 of 4 John Hancock fundsFor—
MBX BIOSCIENCES2026-06-04Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Patrick J. HeronForWITHHOLD — 3 of 4 John Hancock fundsFor—
IMMUNOME INC.2026-06-09To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. James BoylanForWITHHOLD — 3 of 4 John Hancock fundsFor—
BICARA THERAPEUTICS INC.2026-06-09To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Carolyn Ng, Ph.D.ForWITHHOLD — 3 of 4 John Hancock fundsFor—
BICARA THERAPEUTICS INC.2026-06-09To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Christopher Bowden, M.D.ForWITHHOLD — 3 of 4 John Hancock fundsFor—
MAPLIGHT THERAPEUTICS, INC.2026-06-23To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. George PavlovForWITHHOLD — 3 of 4 John Hancock fundsFor—
CVS HEALTH CORPORATION2026-05-14Shareholder Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.AgainstFOR — 6 of 11 John Hancock fundsFor—
UNITED THERAPEUTICS CORPORATION2026-06-26Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.ForAGAINST — 5 of 9 John Hancock fundsForPassed (calculated), 72.0% support
VAXCYTE, INC.2026-06-15DIRECTOR: Halley Gilbert, J.D.ForABSTAIN — 5 of 9 John Hancock fundsFor—
VAXCYTE, INC.2026-06-15DIRECTOR: Olivier Brandicourt MDForABSTAIN — 5 of 9 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Bruce Booth, D.Phil.ForABSTAIN — 4 of 7 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Elena Ridloff, CFAForABSTAIN — 4 of 7 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: John Maraganore, Ph.D.ForABSTAIN — 4 of 7 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Nello Mainolfi, Ph.D.ForABSTAIN — 4 of 7 John Hancock fundsFor—
NATERA, INC.2026-06-11To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated.ForAGAINST — 3 of 5 John Hancock fundsForPassed (calculated), 78.1% support
REPLIGEN CORPORATION2026-05-14Election of Directors Karen A. DawesForAGAINST — 3 of 5 John Hancock fundsFor—
ROYALTY PHARMA PLC2026-06-04Election of Directors David HodgsonForAGAINST — 2 of 3 John Hancock fundsFor—
ROYALTY PHARMA PLC2026-06-04Election of Directors Pablo LegorretaForAGAINST — 2 of 3 John Hancock fundsFor—
BEONE MEDICINES AG2026-06-11THAT MR. JOHN V. OYLER BE AND IS HEREBY RE-ELECTED TO SERVE AS CHAIRMAN OF THE BOARD OF DIRECTORS OF THE COMPANY FOR A TERM EXTENDING UNTIL COMPLETION OF THE 2027 ANNUAL GENERAL MEETINGForAGAINST — 2 of 3 John Hancock fundsFor—

Download all 145 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 75.9% of this fund’s 1,342 such votes could be given a sector; the other 324 (24.1%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care952232.4%
Industrials4924.1%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections7980
Audit-related1590
Say-on-Pay1470
Capital Structure831
Compensation751
Corporate Governance6016
Other220
Other Social Issues73
Human Rights or Human Capital/workforce55
Shareholder Rights and Defenses41

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
ELI LILLY AND COMPANYMay 4, 2026$39M102
ABIVAX SAMay 11, 2026$26M20
THERMO FISHER SCIENTIFIC INC.May 20, 2026$13M130
ARGENX SENovember 18, 2025$13M10
UNITEDHEALTH GROUP INCORPORATEDJune 1, 2026$11M121
MERCK & CO., INC.May 26, 2026$9M183
ABBVIE INC.May 8, 2026$9M81
ARGENX SEMay 6, 2026$9M120

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
June 1, 2026UNITEDHEALTH GROUP INCORPORATEDIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 8, 2026ABBVIE INC.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026VERTEX PHARMACEUTICALS INCORPORATEDShareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
May 19, 2026AMGEN INC.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
May 14, 2026CVS HEALTH CORPORATIONStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalAgainstFor
May 13, 2026ELEVANCE HEALTH, INC.Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposalAgainstFor

Search this fund’s votes by company

1,362 ballot items at 160 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Health Sciences Trust (JAFKX) voted at 160 shareholder meetings of 157 companies, on 1,362 ballot items in all. Where management made a recommendation, the fund followed it on 96.8% of the items and voted against it 27 times. Its most frequent area of disagreement was corporate governance (16 of its votes against management). It voted on 26 shareholder proposals. It voted FOR the board's own proposals more often than John Hancock's funds as a whole (92.0% against 90.1%). It voted differently from most John Hancock funds on 145 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of John Hancock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.